ArticleNature genetics2022
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
19.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 106 citations in OpenAlex.
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- Lethal clinical outcome and immune desert contexture in refractory gastric cancer harboring CCNE1 amplification and overexpression.British journal of cancer · 2026Article
- Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.Nature communications · 2026Article
- pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design.ArXiv · 2026Article
- RAD21 regulation of the enhancer-promoter chromatin loop of RAD51 promotes PARPi resistance in ovarian cancer.Journal of translational medicine · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.NPJ genomic medicine · 2026Article
- Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.Nature communications · 2026Article
- FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.Cell reports · 2026Article
- Spatial tumor evolution panorama of ovarian cancer.Cell reports. Medicine · 2026Article
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression.Communications medicine · 2026Article
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
- Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors.Frontiers in immunology · 2026Article
- A Biologically Informed Vision-Guided Framework for Interpretable T Cell Receptor-Epitope Binding Prediction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.ArXiv · 2025Article
- Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers.Discover oncology · 2025Article
- Review
- Genomic complexity and evolution of high-grade serous ovarian cancer treated with platinum-based chemotherapy: advancing precision oncology beyond BRCA1/BRCA2.Journal of ovarian research · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 17 institutions in 6 countries.
Dale W GarsedPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia. dale.garsed@petermac.org.ORCID http://orcid.org/0000-0003-1223-0121
Ahwan PandeyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2238-1054
Sian FeredayPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8559-8579
Catherine J KennedyThe Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-4465-5784
Kazuaki TakahashiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Kathryn AlsopPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Phineas T HamiltonThe Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
Joy HendleyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Yoke-Eng ChiewThe Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Nadia TraficantePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Pamela ProvanThe Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8346-2603
Dinuka AriyaratnePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5704-9030
George Au-YeungPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Nicholas W BatemanWomen's Health Integrated Research Center, Gynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4425-9511
Leanne BowesPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Alison BrandDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Elizabeth L ChristiePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-9959-7024
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8159-3025
Michael FriedlanderPrince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Bronwyn Grout, Sydney, New South Wales, Australia.
Paul HarnettThe University of Sydney, Sydney, New South Wales, Australia.
Jillian HungThe Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Bryan McCauleyDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Orla McNallyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Anna M PiskorzCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Flurina A M SanerPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2469-9824
Robert A VierkantDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6242-5221
Chen WangDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2638-3081
Stacey J WinhamDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8492-9102
Paul D P PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-8494-732X
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5738-6683
Thomas P ConradsWomen's Health Integrated Research Center, Gynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4742-3281
George L MaxwellWomen's Health Integrated Research Center, Gynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.
Susan J RamusSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-0005-7798
Celeste Leigh PearceDepartment of Epidemiology and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Malcolm C PikeDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brad H NelsonThe Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.ORCID http://orcid.org/0000-0002-4445-5539
Ellen L GoodeDivision of Epidemology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Anna DeFazio *The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-0057-4744
David D L Bowtell *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. david.bowtell@petermac.org.ORCID http://orcid.org/0000-0001-9089-7525
The University of Melbourne · AUThe University of Sydney · AUMayo Clinic in Florida · USPeter MacCallum Cancer Centre · AUUniversity of Cambridge · GBInova Health System · USRoyal Women's Hospital · AUUNSW Sydney · AUCancer Institute of New South Wales · AUHenry M. Jackson Foundation · USJikei University School of Medicine · JPMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USUniversity of Bern · CHUniversity of British Columbia · CAUniversity of Michigan · USWestmead Hospital · AU
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MXenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MProject 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5MRelating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8MCancer Research UK 15601Cancer Research UK 22905Cancer Research UK A22905NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA248288NCI NIH HHS U54 CA209978
Abstract
Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long survival could provide insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes and differential immune responses appear to contribute to long-term survival in HGSC.
Indexed as
GenomicsOvarian NeoplasmsFemaleHumansSurvivors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.